Author

Eliza Wright Beal

Wayne State UniversityORCID 0000-0003-2191-6811Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Allan M. JohanseniD· 2 shared Amro AboukameeliD· 2 shared Bassel F. El‐RayesiD· 2 shared Boris PascheiD· 2 shared Gregory E. DysoniD· 2 shared Herbert R. CheniD· 2 shared Hugo JimeneziD· 2 shared Husain Yar KhaniD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Allan M. JohansenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyInternational Journal of Biological SciencesPeer-reviewedSep 3, 2026

Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways

Md. Hafiz Uddin, Zaid K Mahdi, Irfana Muqbil…·Asfar S. Azmi

This study identifies key oncogenic pathways and targetable genes in MEN1-wild-type low-grade pancreatic NETs that drive metastasis, offering a therapeutic strategy based on pathway intensity rather than mutation count.

DOI 10.7150/ijbs.134269

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 21, 2025

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma

Husain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel…·Asfar Sohail Azmi

This paper shows that combining Eltanexor and MRTX1133 improves efficacy in KRASG12D mutant PDAC by overcoming resistance and reducing tumor growth.

DOI 10.1101/2025.11.21.689857

humanmouse

𝕏 PostBluesky